ClearPoint Neuro, Inc. has successfully completed the acquisition of IRRAS Holdings, Inc.
The acquisition will enhance ClearPoint Neuro's commercial scale and support its long-term strategy in CNS drug delivery innovation.
As part of the transaction, ClearPoint Neuro paid $5.0 million in cash and issued 1,325,000 shares of its common stock to IRRAS shareholders.
Acquisition Details
ClearPoint Neuro paid $5.0 million in cash and issued 1,325,000 shares of its common stock to IRRAS shareholders.
Technology Acquisition
The acquisition brings IRRA flow active fluid-exchange system, a technology aimed at modernizing intracranial bleeding management, to ClearPoint Neuro.
Resource Expansion
IRRAS brings more than 50 active customers and a commercial team of marketing, sales, and clinical specialists to ClearPoint Neuro.
- The acquisition allows ClearPoint Neuro to expand its presence in neurocritical care and complement its existing portfolio of neurosurgical technologies and drug delivery platforms.
- The addition of IRRAS resources is expected to drive meaningful value for stakeholders by enhancing ClearPoint Neuro's commercial scale and reaching a larger patient base.
The completion of the IRRAS acquisition marks a significant milestone in ClearPoint Neuro's strategy to build the leading platform for neuro drug delivery, positioning the company for future growth and innovation.